• #21 : Pfizer's New Obesity Drug

  • Jan 13 2025
  • Length: 4 mins
  • Podcast

#21 : Pfizer's New Obesity Drug

Listen for free

View show details

  • Summary

  • Pfizer is heavily investing in its experimental obesity drug, danuglipron, aiming for a once-daily oral pill to compete with the currently dominant injectable weight-loss treatments from Eli Lilly and Novo Nordisk. CEO Albert Bourla expressed cautious optimism, anticipating data from dose-testing studies within months and a potential market entry as the second oral option. While Pfizer is not pursuing acquisitions in the injectable GLP-1 market, they remain open to acquiring other types of obesity treatments. The company's goal is to provide a convenient and competitive alternative in a market projected to reach $150 billion annually by the early 2030s. The unrelated mention of a "Bio Leg" device suggests extraneous information included in the source material.

    Hosted on Acast. See acast.com/privacy for more information.
    Show more Show less
Show more Show less

What listeners say about #21 : Pfizer's New Obesity Drug

Average customer ratings

Reviews - Please select the tabs below to change the source of reviews.

Audible.com reviews

Amazon reviews
No Reviews are Available